Sponsor or institution

Clinical trials and research at Fudan University

• 335Clinical trials
• 4New in 30 days
• 1Country

Newest trials

All recruiting trials (newest 150 of 335)

• Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease in Real World Practice

  This study will look at real-world safety and effectiveness of disease-modifying therapy (DMT) in adults with MCI or Alzheimer's dementia by comparing those who receive DMT in routine care to those who do not.

  Recruiting Fudan University · Shanghai, Jingan · NCT07923812

• ctDNA methylation-guided adjuvant therapy after removing colorectal liver metastases

  This trial tests whether using a blood test that detects ctDNA methylation after surgery can guide adjuvant therapy for patients who had colorectal cancer spread to the liver and were operated on with no remaining disease.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07917104

• China HEAD: a large community study on healthy aging and dementia

  This study tests whether collecting health, imaging, and biospecimen data from adults in China can help predict who will develop Alzheimer’s disease and related dementias.

  Recruiting at 30 sites Fudan University · Beijing and 29 other locations · NCT07912710

• Becotatug Vedotin plus Pucotenlimab for EGFR-positive metastatic colorectal cancer

  This study tests whether combining becotatug vedotin with pucotenlimab can shrink tumors in adults with colorectal cancer that has returned or spread after at least two prior treatments and whose tumors express EGFR.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07884188

• ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer

  This study tests whether tracking ctDNA can guide neoadjuvant immunotherapy and surgical decisions for people with dMMR/MSI-H colon cancer, using PD-1 inhibitors first and adding CTLA-4 inhibitors if ctDNA remains detectable.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07841236

• Hypofractionated vs. standard radiotherapy after mastectomy with implant reconstruction

  This trial tests whether shorter, higher-dose radiotherapy schedules after implant-based mastectomy reconstruction work as well as the traditional longer schedules for preventing unplanned reoperations.

  Recruiting Fudan University · Shanghai · NCT07835139

• One-week versus three-week partial breast irradiation for early-stage breast cancer

  This trial tests whether a shorter one-week partial breast irradiation plan is not worse than a three-week plan for women after breast-conserving surgery.

  Recruiting Fudan University · Shanghai · NCT07832279

• Response-Adapted Omission of Nodal Boost in N3 Breast Cancer After NST

  This trial tests whether skipping the radiation boost to undissected nodal areas after neoadjuvant therapy is as effective as giving the boost for people with high-risk N3 breast cancer.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07829848

• FAPI-guided radiotherapy with cadonilimab plus chemo for colorectal cancer limited to the peritoneum

  Aims to see if adding targeted radiotherapy and cadonilimab immunotherapy to standard second-line chemotherapy helps adults with colorectal cancer that’s spread only to the peritoneum.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT07815834

• Olive oil before lung cancer surgery to see if it lowers chylothorax

  This study tests whether drinking 40 mL of extra-virgin olive oil a few hours before lung cancer surgery can reduce chylothorax after tumor removal.

  Recruiting Fudan University · Shanghai, Xuhui · NCT07807696

• Left-lung cancer: is removing station 4L lymph nodes necessary for early-stage tumors?

  In adults with a small, single solid tumor in the left lung, the study tests whether skipping station 4L lymph node dissection during surgery is as safe as doing it.

  Recruiting Fudan University · Shanghai, Xuhui · NCT07801430

• Niraparib as first-line maintenance for advanced ovarian cancer

  This real-world, non-interventional study looks at how niraparib used as first-line maintenance works in women with advanced ovarian cancer in routine care.

  Recruiting Fudan University · Shanghai · NCT07783022

• Selective coverage radiotherapy vs. full coverage radiotherapy for poorly differentiated and anaplastic thyroid cancer

  This trial tests whether covering only the tumor-affected area with radiation is as effective as full-area coverage radiotherapy for poorly differentiated and anaplastic thyroid cancer, while aiming to reduce side effects and improve quality of life.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07777536

• One-stop CT-Linac radiotherapy for breast cancer

  This trial tests a fully automated, single-session radiotherapy workflow to see if it works safely for people with breast cancer.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07776301

• Dynamic risk-guided EBV-DNA and MRI-based chemotherapy adjustments in nasopharyngeal carcinoma

  This trial tests whether adjusting adjuvant therapy based on changes in EBV DNA and MRI findings after radiotherapy helps improve outcomes for people with nasopharyngeal carcinoma.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07762976

• Omitting post-surgery radiotherapy for young women with low-risk DCIS after breast-conserving surgery

  In young women with small, low-risk DCIS treated with lumpectomy, doctors are testing whether skipping postoperative radiotherapy is safe and see if close follow-up is enough.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07762924

• Omission of Radiotherapy After Breast-Conserving Surgery for Certain DCIS Patients

  This trial tests whether skipping postoperative radiotherapy is okay for women with low- or intermediate-risk DCIS after breast-conserving surgery.

  Recruiting Phase 3 Fudan University · Shanghai · NCT07762885

• Is surgery helpful after radiological response in advanced gastric cancer when conversion therapy works?

  This study tests whether adding radical surgery after a strong radiological response to conversion therapy improves outcomes for patients with advanced metastatic gastric cancer.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07757165

• Epstein-Barr virus–positive T/NK-cell lymphoproliferative diseases in large patient groups

  This study follows patients with EBV-positive T/NK-cell disorders to see how they present, what treatments are used, and how they respond over time.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07727083

• Canagliflozin for Type 2 Diabetes with Mild Cognitive Impairment

  This study tests whether canagliflozin can help people with type 2 diabetes and mild cognitive impairment see if their thinking and memory improve.

  Recruiting Phase 4 Fudan University · Shanghai, Shanghai Municipality · NCT07711171

• Young patients with solid tumors in China: real-world outcomes

  This study in China tests how organ and fertility preservation, plus long-term quality of life, fare for young adults with malignant solid tumors using data from routine care.

  Recruiting Fudan University · Shanghai · NCT07708935

• Granzyme B-PET to see if immunotherapy works in TNBC

  This study will test whether a Granzyme B PET/CT scan can help predict how well immunotherapy will work for adults with locally advanced or metastatic triple-negative breast cancer receiving an immune checkpoint inhibitor.

  Recruiting Fudan University · Shanghai · NCT07705438

• PD-1 inhibitors with local therapy at different timings in oligometastatic ESCC

  This study tests whether giving local radiotherapy at different times around PD-1 inhibitor therapy helps people with oligometastatic esophageal squamous cell carcinoma.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07697859

• Frontline immunotherapy versus chemotherapy induction for advanced Extranodal NK/T-cell lymphoma, followed by autologous stem cell transplant

  This study tests whether starting with immunotherapy plus targeted drugs is more effective than standard chemotherapy to help patients with advanced extranodal NK/T‑cell lymphoma, then all patients who reach a strict remission proceed to autologous stem cell transplantation.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT07678229

• Culmerciclib Rechallenge with Fulvestrant in HR-positive, HER2-negative Breast Cancer after Endocrine Therapy

  This study tests whether adding Culmerciclib to fulvestrant works better than a CDK4/6 inhibitor plus fulvestrant for women with HR-positive, HER2-negative breast cancer whose initial endocrine therapy stopped working.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07666555

• Cancer-related fatigue in Chinese patients with cancer

  This OBSERVATIONAL study tests how often and how severely fatigue occurs in adults with cancer and looks at factors that influence it and how fatigue relates to treatment and outcomes.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07656324

• Brain metastases from breast cancer: see how trastuzumab deruxtecan in CSF relates to effect

  This study tests whether levels of trastuzumab deruxtecan in cerebrospinal fluid relate to how well it works for adults with breast cancer that has spread to the brain.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07653893

• Hetrombopag for secondary prevention of chemotherapy-induced thrombocytopenia in breast cancer

  This study tests whether hetrombopag can help breast cancer patients who are at high risk of low platelets during chemotherapy.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07647029

• Trastuzumab Deruxtecan plus ivonescimab for HR+ HER2-low advanced breast cancer

  This study tests whether combining Trastuzumab Deruxtecan with ivonescimab can help people with HR-positive, HER2-low metastatic breast cancer after prior CDK4/6 inhibitor therapy.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07647016

• Radiotherapy with chemotherapy plus adebrelimab and bevacizumab for TNBC with brain metastases

  This phase II study tests a combination of radiotherapy, cisplatin or carboplatin, adebrelimab, and bevacizumab in adults with triple-negative breast cancer that has spread to the brain.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07638852

• Can compression or ice gloves and socks reduce neuropathy from UTD1 in advanced breast cancer

  This randomized phase III trial tests whether compression gloves/socks or ice gloves/socks can reduce nerve problems in women with advanced breast cancer undergoing UTD1 treatment.

  Recruiting Fudan University · Shanghai · NCT07638774

• How screening patterns relate to early-stage lung cancer in newly diagnosed patients

  This study looks at how different lung cancer screening behaviors relate to catching cancer early in patients who were recently diagnosed.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07626177

• Sac-TMT plus bevacizumab in TNBC with brain metastases

  This phase II, single-arm study tests whether Sac-TMT combined with bevacizumab can help people with triple-negative breast cancer and brain metastases.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07623577

• Pyrotinib and Trastuzumab with Dalpiciclib vs with Docetaxel in advanced HER2-positive breast cancer

  This study tests whether an oral regimen of pyrotinib + subcutaneous trastuzumab + dalpiciclib works as well as the standard IV regimen with docetaxel in people with advanced HER2-positive breast cancer who have limited prior treatment.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT07615751

• Serplulimab plus second-line chemo/targeted therapy for early-relapse colorectal cancer after adjuvant therapy

  This trial tests whether adding serplulimab to standard second-line chemotherapy plus targeted therapy helps people whose colorectal cancer came back early after adjuvant treatment.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07604909

• HER2-PET to Predict T-DXd Benefit in Advanced Breast Cancer

  This study tests whether HER2-PET imaging can help predict how well T-DXd will work for adults with advanced HER2-positive or HER2-low breast cancer receiving the drug.

  Recruiting Fudan University · Shanghai · NCT07586215

• Paclitaxel micelles with HER2-targeted therapy vs standard taxane-based therapy as first-line treatment for advanced HER2-positive breast cancer

  This study tests whether paclitaxel polymer micelles plus trastuzumab, pertuzumab, and ad Adelumab can better treat advanced HER2-positive breast cancer compared with the usual taxane-based therapy plus trastuzumab and pertuzumab.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07581795

• Comparing Shengbai oral liquid and Leucogen tablets for moderate chemotherapy‑related neutropenia in breast cancer

  This study tests whether Shengbai oral liquid or Leucogen tablets work better to treat moderate neutropenia in people with breast cancer who are receiving anti‑tumor drugs.

  Recruiting Phase 4 Fudan University · Shanghai, Shanghai Municipality · NCT07578064

• Blood microchip test using breast cancer small extracellular vesicles to identify molecular subtypes

  This test will try a blood-and-tissue microchip method using small extracellular vesicles to identify molecular subtypes in adults with unresectable or metastatic breast cancer.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07574749

• Using plasma ctDNA methylation to guide adjuvant chemotherapy for high-risk T3N0 colorectal cancer

  This will test whether a blood ctDNA methylation test can help choose stronger chemotherapy after surgery for people with high-risk T3N0 (stage II) colorectal cancer who are ctDNA-positive one month after surgery.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07562711

• Plasma ctDNA methylation-guided adjuvant chemotherapy for stage I / low-risk stage II colorectal cancer

  This trial will test whether using a blood test for ctDNA methylation one month after surgery to guide adjuvant chemotherapy (such as capecitabine) helps clear ctDNA and lower recurrence risk in adults with stage I or low-risk stage II colorectal cancer who are ctDNA-positive.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07562659

• Plasma ctDNA methylation-guided adjuvant chemotherapy for people with T4N0 and low‑risk stage III colorectal cancer.

  This trial will test whether using a blood test (plasma ctDNA methylation) to guide 3 vs 6 months of adjuvant chemotherapy or to switch regimens helps people with T4N0 or low‑risk stage III colorectal cancer after surgery.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07562503

• Plasma ctDNA methylation–guided adjuvant chemotherapy for high-risk stage III colorectal cancer

  This trial will test whether adding bevacizumab to standard FOLFOX or CAPOX chemotherapy based on plasma ctDNA results helps adults with high-risk stage III colorectal cancer (T4N+ or T1-3N2).

  Recruiting Phase 2 Fudan University · Shanghai · NCT07562490

• Total neoadjuvant therapy with concurrent tislelizumab for low rectal cancer

  This trial tests whether adding the immunotherapy drug tislelizumab to total neoadjuvant chemotherapy helps adults with low rectal cancer reach a complete response so some can avoid major surgery.

  Recruiting Phase 1/2 Fudan University · Shanghai, Shanghai Municipality · NCT07561060

• KRAS-mutant pancreatic cancer: a multicenter database for targeted therapy

  This project builds a real-world, multicenter cohort to see how well KRAS-targeted therapies work for people with pancreatic cancer who have KRAS mutations.

  Recruiting Fudan University · Shanghai · NCT07557849

• Can non-contrast chest CT help screen for breast cancer alongside standard imaging

  This study looks at whether non-contrast chest CT done for other reasons can help detect breast cancer and how its results compare with mammography or breast MRI.

  Recruiting Fudan University · Shanghai · NCT07557654

• Combining anti‑PD‑1 immunotherapy with chemoradiation for anal squamous cell cancer

  This trial tests whether adding an anti‑PD‑1 immunotherapy drug to standard chemoradiation helps people with localized or locally advanced anal squamous cell carcinoma get better responses and have fewer recurrences.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07555678

• Compared immunotherapy timings in resectable stage II-IIIA NSCLC

  In people with resectable stage II-IIIA non-small cell lung cancer, this study will test three timing approaches of the anti-PD-1 therapy toripalimab to see which works best when given around surgery.

  Recruiting Phase 3 Fudan University · Shanghai · NCT07554846

• Patient-reported outcomes of sacituzumab govitecan versus physician‑choice chemotherapy in Chinese metastatic HER2‑negative breast cancer

  This project will test whether sacituzumab govitecan or physician‑choice chemotherapy leads to better patient‑reported quality of life and symptoms for Chinese adults aged 18–75 with metastatic HER2‑negative breast cancer who progressed after first‑line treatment.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07551050

• Pinoxin to prevent radiation skin injury

  See if spraying Pinoxin four times daily can prevent skin damage in adults receiving long-course radiotherapy (≥50 Gy) with radiation fields near the skin.

  Recruiting at 2 sites Phase 2 Fudan University · Shanghai, Shanghai Municipality and 1 other locations · NCT07545720

• AK104 plus radiotherapy with standard first-line treatment for pMMR/MSS colorectal cancer liver metastases

  This trial will test whether adding AK104 and targeted liver radiotherapy to standard first-line therapy helps people with pMMR/MSS colorectal cancer that has spread to the liver.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07544784

• Digital music-and-biofeedback mind-body program during pre-surgery chemotherapy for breast cancer

  This trial tests a smartphone-delivered music and biofeedback mind-body program to help people with locally advanced breast cancer who are receiving neoadjuvant therapy.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07541664

• Becotatug vedotin (MRG003) for previously treated advanced liver cancer with EGFR testing

  This study will test whether Becotatug vedotin (MRG003) helps people with advanced hepatocellular carcinoma whose cancer progressed after PD‑1/L1 therapy.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07536789

• AI-guided neoadjuvant therapy for HER2-positive breast cancer

  This trial tests whether an artificial intelligence–matched anti-HER2 treatment approach improves outcomes for adults with early- to locally advanced HER2-positive breast cancer compared with standard chemo plus anti-HER2 therapy.

  Recruiting Phase 3 Fudan University · Shanghai · NCT07528716

• Using blood tests for circulating tumor DNA to guide treatment in gastric cancer

  This will test whether regular blood tests that measure circulating tumor DNA can help guide systemic treatment for adults with gastric or gastroesophageal junction adenocarcinoma.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07517107

• Cetuximab with PD-1 therapy plus chemotherapy vs PD-1 therapy with chemotherapy for recurrent/metastatic head and neck cancer

  This trial tests whether adding cetuximab to a PD-1 inhibitor plus chemotherapy helps people with recurrent or metastatic head and neck squamous cell cancer who aren’t candidates for curative treatment.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality and 1 other locations · NCT07509099

• Chidamide maintenance for MRD-positive double-expressor DLBCL in first remission

  This study tests whether giving chidamide as maintenance therapy can help people with double-expressor DLBCL who have complete remission but still have MRD detected in their blood.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07507318

• Air purifier use and COPD health in adults: a home-based study

  This randomized trial tests whether using a real air purifier at home improves respiratory health in adults with COPD compared to a sham purifier.

  Recruiting Fudan University · Shanghai · NCT07505602

• Tislelizumab plus Zeprumetostat in relapsed or refractory NK/T-cell lymphoma

  This study tests whether combining tislelizumab with zeprumetostat can help patients with relapsed or refractory NK/T-cell lymphoma after prior chemotherapy.

  Recruiting Phase 1/2 Fudan University · Shanghai, Shanghai Municipality · NCT07502768

• Beocotatug Vedotin plus Pucotenlimab for EGFR-positive advanced penile cancer

  This trial tests whether a targeted antibody-drug conjugate plus a PD-1 inhibitor can help people with EGFR-positive advanced penile cancer who have limited or no chemotherapy options.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07497919

• Sintilimab plus SOX chemotherapy versus SOX alone after surgery for stomach or gastroesophageal junction adenocarcinoma

  This trial will test whether adding sintilimab to SOX chemotherapy after surgery helps people with stage IIIC or dMMR/MSI‑H stage IIIA/IIIB stomach or gastroesophageal junction cancer stay disease‑free longer.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07492615

• TROP2‑PET and FDG‑PET to predict response to anti‑TROP2 antibody‑drug therapy in advanced HER2‑negative breast cancer

  See if combining a TROP2 PET scan with an FDG PET scan can predict who with advanced HER2‑negative breast cancer will respond to anti‑TROP2 antibody‑drug treatments.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality and 1 other locations · NCT07471776

• Level I–II axillary radiation versus whole regional nodal radiation after surgery for breast cancer with 1–2 sentinel-node macrometastases.

  This will test whether limiting radiation to level I–II axillary lymph nodes works as well as whole regional nodal radiation for women with early breast cancer and 1–2 sentinel-node macrometastases.

  Recruiting Fudan University · Guiyang, Guizhou and 14 other locations · NCT07469267

• Testing MRG003 alone or with putrelimab for recurrent or metastatic salivary gland cancer

  This trial tests whether MRG003, by itself or combined with putrelimab, can help people with recurrent or metastatic salivary gland cancers that show EGFR on their tumors.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07464366

• Combined multimodal tumor therapy system for liver cancer

  Aims to test a multimodal tumor treatment that combines thermal ablation with immune-based approaches for adults with primary or metastatic liver cancer who can’t have surgery.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07459309

• SHR-1701 plus focused stereotactic radiation for metastatic castration‑resistant prostate cancer

  This study will test whether adding the immune drug SHR‑1701 to focused stereotactic body radiotherapy (SBRT) can help men with metastatic castration‑resistant prostate cancer who have progressed after next‑generation hormone therapy.

  Recruiting at 3 sites Phase 2 Fudan University · Fujian and 2 other locations · NCT07451795

• Tunlametinib for NRAS‑mutant advanced melanoma after PD‑1/PD‑L1 therapy

  This study will test whether the oral drug tunlametinib helps adults with NRAS‑mutant advanced melanoma who did not respond to anti‑PD‑1/PD‑L1 therapy.

  Recruiting Phase 4 Fudan University · Shanghai · NCT07445022

• Chemotherapy-free therapy with a CDK4/6 inhibitor for small high-risk ER-positive breast cancer

  This trial tests whether adding the CDK4/6 inhibitor dalpiciclib with endocrine therapy can spare chemotherapy for small, high-risk ER-positive, HER2-negative breast cancers.

  Recruiting Phase 3 Fudan University · Shanghai · NCT07432178

• AI-enhanced breast imaging for population screening

  This project will test whether combining AI-assisted breast ultrasound and AI-assisted mammography improves detection accuracy and efficiency for women aged 35–69 in population-based breast cancer screening.

  Recruiting Fudan University · Shanghai, Shaghai · NCT07411443

• Vebrekotuzumab with or without anti-PD-1 for previously treated advanced esophageal squamous cell carcinoma

  This trial will test whether the EGFR-targeted antibody-drug conjugate vebrekotuzumab, alone or with an anti-PD-1 drug, helps people with advanced esophageal squamous cell carcinoma whose disease progressed after prior treatment.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07403136

• PD-1 antibody plus first-line chemotherapy for metastatic gastric cancer and gut bacteria

  This project will try combining a PD-1 antibody with standard first-line chemotherapy in people with advanced gastric cancer to see if gut bacteria predict who benefits.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07400354

• Serplulimab versus nivolumab with chemotherapy before surgery for resectable stage II–IIIA squamous lung cancer

  This study will test whether giving serplulimab plus chemotherapy before surgery works better than nivolumab plus chemotherapy in adults with resectable stage II–IIIA squamous non-small cell lung cancer.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07398937

• Metformin for older overweight adults with mild cognitive impairment

  This will test whether taking metformin alongside lifestyle changes can help thinking and memory in older overweight adults with mild cognitive impairment.

  Recruiting Phase 1/2 Fudan University · Shanghai · NCT07395960

• Using blood ctDNA changes to guide treatment for HER2‑negative metastatic breast cancer

  This study will try using early drops in circulating tumor DNA (ctDNA) after two cycles of antibody‑drug conjugate therapy to decide whether to intensify treatment for people with HER2‑negative metastatic breast cancer.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07394218

• Second-line albumin-bound paclitaxel regimens for advanced gastric or gastroesophageal junction cancer

  This project tries different second-line treatments based on albumin-bound paclitaxel to see which helps people with advanced gastric or gastroesophageal junction cancer whose first-line chemotherapy plus immunotherapy has stopped working.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07389876

• PULSAR pulsed radiotherapy combined with anti‑PD‑1 therapy for metastatic liver, kidney, or bladder cancers

  This trial tests if pulsed hypofractionated radiotherapy together with anti‑PD‑1 immunotherapy helps people with metastatic hepatocellular, renal cell, or urothelial carcinoma control their disease.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07383857

• Unrelated umbilical cord blood transplant for EBV-associated lymphoproliferative diseases

  This trial will try an unrelated umbilical cord blood transplant to treat people aged 14–80 with EBV-associated lymphoproliferative diseases, including chronic active EBV and EBV-related lymphoma.

  Recruiting at 2 sites Phase 2 Fudan University · Shanghai, Shanghai Municipality and 1 other locations · NCT07381738

• Comparing quadrant-based, subtotal, and total intersphincteric resections for ultra-low rectal cancer

  This compares a quadrant-tailored intersphincteric resection to subtotal and total ISR to see if it preserves anal function without compromising cancer control in people with ultra-low rectal cancer who are candidates for sphincter-preserving surgery.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07371273

• Using corticosteroids to reduce hand–foot skin reactions from liposomal doxorubicin

  This study will test whether giving corticosteroids around doses of liposomal doxorubicin can reduce painful hand–foot skin reactions in people with breast cancer receiving AC chemotherapy.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT07362914

• G‑CSF plus IL‑11 for faster blood recovery after autologous stem cell transplant

  This phase 2 trial will test whether adding IL‑11 to G‑CSF improves mobilization and speeds platelet and red blood cell recovery in adults having autologous stem cell transplant for multiple myeloma or lymphoma.

  Recruiting at 7 sites Phase 2 Fudan University · Fuzhou, Fujian and 6 other locations · NCT07362810

• RGL-270 vaccine alone or with adebelimab to lower risk of cancer coming back after surgery

  This phase I trial will test whether a personalized mRNA vaccine called RGL-270, given alone or with the immune drug adebelimab, can help prevent recurrence in adults who had radical treatment for high‑risk malignant solid tumors.

  Recruiting Phase 1 Fudan University · Shanghai · NCT07348042

• External Oblique Intercostal Plane Block to Ease Pain After Major Upper Abdominal Surgery

  This study tests whether adding a bilateral External Oblique Intercostal Plane Block helps reduce pain and opioid use after major upper abdominal laparoscopic surgery.

  Recruiting Fudan University · Shanghai · NCT07331441

• Personalized adaptive second-line treatments for advanced liver cancer

  This trial tries different personalized second-line treatments to find which work best for people with advanced hepatocellular carcinoma after first-line immunotherapy-based regimens stop working.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07328009

• Fertility-preserving care for endometrial cancer guided by tumor molecular type

  This trial tests whether choosing fertility-preserving medicines based on a tumor's molecular subtype helps women with early endometrial cancer keep their fertility.

  Recruiting Phase 2/3 Fudan University · Shanghai, Shanghai Municipality and 1 other locations · NCT07319429

• Trastuzumab rezetecan for HER2-positive advanced solid tumors resistant to standard treatments

  This treatment gives trastuzumab rezetecan every three weeks to see if it helps adults with HER2-positive advanced solid tumors — including extramammary Paget's disease, rare tumors like urachal cancer, and urothelial carcinoma — that have stopped responding to standard treatments.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07309770

• Individualized neck irradiation for nasopharyngeal carcinoma

  This trial will test whether tailoring how far the neck is radiated based on each patient's lymph node spread works as well as standard broader neck radiation for adults with newly diagnosed, non-metastatic nasopharyngeal carcinoma.

  Recruiting at 2 sites Phase 3 Fudan University · Shanghai, Shanghai Municipality and 5 other locations · NCT07303023

• Remifentanil dosing and clearance in low-weight ICU patients

  This study will test how remifentanil is processed in the body and how it affects blood pressure and sedation in low-body-weight adults on mechanical ventilation in the ICU.

  Recruiting Fudan University · Shanghai · NCT07301970

• Golidocitinib versus placebo as maintenance for peripheral T-cell lymphoma

  This trial will test whether taking golidocitinib every other day can help keep peripheral T‑cell lymphoma in remission for adults who responded to first‑line chemotherapy and are not having a stem cell transplant.

  Recruiting Phase 3 Fudan University · Shanghai · NCT07300514

• How mental health relates to immunotherapy response in triple-negative breast cancer

  This project tries to see if a patient's mental health affects how well pre-surgery immunotherapy works for people with early triple-negative breast cancer.

  Recruiting Fudan University · Shanghai, Please Select · NCT07290153

• Using ctDNA methylation to monitor treatment for metastatic colorectal cancer

  We will test whether measuring ctDNA methylation in blood can track treatment response and predict relapse for adults with recurrent or metastatic colorectal cancer receiving radiotherapy plus standard chemotherapy, with or without PD‑1 immunotherapy.

  Recruiting Fudan University · Shanghai · NCT07283575

• Fever clinic tracking of acute respiratory infections

  This project follows adults who come to a fever clinic with respiratory infections to see how their symptoms, test results, and outcomes change over time.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07278700

• Omega-3 supplements with PD-1 therapy for advanced esophageal cancer

  This trial will test whether taking omega-3 fish oil (EPA+DHA) together with PD-1 immunotherapy helps adults with recurrent or metastatic esophageal cancer maintain muscle and have better clinical and patient-reported outcomes than a placebo.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07272382

• Real-world outcomes for peripheral T‑cell lymphoma in Chinese adults

  This project will collect past and new clinical and molecular data to see which treatments and biomarkers work best for adults in China with peripheral T‑cell lymphoma.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07270861

• TACE with QL1706 around surgery for liver cancer that goes beyond Milan criteria

  This trial tests whether giving TACE together with QL1706 around the time of surgery is safe and helpful for adults with resectable hepatocellular carcinoma that exceeds Milan criteria.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07268131

• How opioid-free, opioid-sparing, and opioid-based anesthesia affect immune markers and cancer cell behavior after colorectal cancer surgery

  This trial will test whether opioid-free or opioid-sparing anesthesia versus standard opioid-based anesthesia changes immune markers and affects cancer cell behavior in adults having elective colorectal cancer surgery.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07264556

• Predictors of response to CD19 CAR-T therapy in relapsed/refractory large B‑cell lymphoma

  This study will see if clinical features, tumor biology, and immune cell changes can predict who responds to CD19 CAR‑T therapy for relapsed/refractory large B‑cell lymphoma.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07236203

• MRG003 plus pucotenlimab for EGFR-positive advanced anaplastic or poorly differentiated thyroid cancer

  This trial will see if combining MRG003 and pucotenlimab can help adults with EGFR-positive unresectable or metastatic anaplastic or poorly differentiated thyroid cancer by shrinking tumors or slowing their growth.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07235566

• Disitamab Vedotin plus BCG vs BCG alone in HER2-expressing high-risk NMIBC

  This study tests whether adding disitamab vedotin to BCG helps people with early, high-risk bladder cancer that hasn’t spread outside the bladder.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT07207824

• Why entrectinib stops working in ROS1-positive non-small cell lung cancer

  This project will test what genetic changes cause entrectinib to stop working in adults with ROS1-positive non-small cell lung cancer by analyzing blood and tissue samples collected during routine care.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07199959

• Conversion therapy using disitamab vedotin (RC48), sintilimab, and SOX for HER2 IHC 1+ or 2+ unresectable gastric cancer

  This trial will test whether combining disitamab vedotin (RC48), the immunotherapy sintilimab, and SOX chemotherapy can shrink tumors enough to allow surgery in people with initially unresectable HER2 IHC 1+ or 2+ gastric cancer.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07194005

• Short-course radiation with liposomal irinotecan, anti–PD-1, and targeted therapy for locally recurrent rectal cancer

  This trial will test whether short-course radiation plus liposomal irinotecan (NALIRIF) with 5‑FU/leucovorin, an anti–PD‑1 drug, and targeted therapy can shrink pelvic recurrences in patients with locally recurrent rectal cancer who have already failed oxaliplatin.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07183865

• Multicenter database for pancreatic solid pseudopapillary neoplasm

  This project will collect clinical, pathology, treatment, and follow-up data from people with pancreatic solid pseudopapillary neoplasm to build a multicenter database to help guide care.

  Recruiting Fudan University · Shanghai, Special Administrative Region · NCT07183280

• SKB264 with inetetamab for HER2-positive advanced breast cancer after progression on T-DXd

  This trial will see if combining SKB264 and inetetamab helps adults with HER2-positive unresectable or metastatic breast cancer whose disease progressed after trastuzumab deruxtecan (T-DXd).

  Recruiting Phase 2 Fudan University · Shanghai · NCT07182721

• How often esophageal cancer spreads to the left tracheobronchial (106TBL) lymph nodes

  See how often and which factors are linked to spread to the left tracheobronchial (106TBL) lymph nodes in people with esophageal squamous cell carcinoma who are having curative esophagectomy.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07165210

• How often esophageal cancer spreads to the subcarinal (107) lymph node

  This study will try to find how often esophageal squamous cell carcinoma spreads to the subcarinal (107) lymph node and which patients are more likely to have that spread when they undergo esophagectomy.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07165184

• Compression stockings to prevent peripheral neuropathy in patients receiving MMAE-containing ADCs for urothelial cancer

  This study will test whether wearing a medical compression stocking on one foot during antibody–drug conjugate (MMAE-containing) infusions can prevent peripheral neuropathy in adults with advanced urothelial carcinoma or other cancers.

  Recruiting Fudan University · Shanghai · NCT07164950

• Multimodal Thermal Therapy for Malignant Liver Tumors

  This study tests a combined cryo- and heat-based therapy to see if it can help people with liver cancers live longer and have fewer tumors.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07159048

• Comparing long-course chemoradiation versus short-course radiation plus CAPOX, a PD-1 blocker (serplulimab), and celecoxib for locally advanced rectal cancer

  This trial will test whether adding CAPOX, the PD-1 drug serplulimab, and celecoxib to short-course radiotherapy works better than standard long-course chemoradiation for adults with MSS locally advanced rectal cancer.

  Recruiting at 5 sites Phase 2 Fudan University · Fuzhou, Fujian and 4 other locations · NCT07154316

• T-DXd with or without Neratinib for HER2-positive breast cancer with brain metastases

  This trial tests whether adding Neratinib to Trastuzumab Deruxtecan helps treat HER2-positive breast cancer that has spread to the brain.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07152782

• Long-course chemoradiation or short-course radiation with CAPOX, PD-1 antibody, and celecoxib for MSS locally advanced rectal cancer

  This trial tests whether adding a PD‑1 immune drug and the anti‑inflammatory celecoxib to standard CAPOX chemotherapy with either long- or short-course radiotherapy helps people with MSS locally advanced rectal cancer achieve a complete response before surgery.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07150949

• Bevacizumab added or not to T-DXd for HER2-low breast cancer with brain metastases

  This trial tests whether adding bevacizumab to trastuzumab deruxtecan helps people with HER2-low breast cancer that has spread to the brain.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07150208

• Comparing first-line immunotherapy combinations for advanced liver cancer

  We will try different first-line immunotherapy combinations to see which works best for people with advanced hepatocellular carcinoma.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07147101

• Intrathecal/Ommaya T-DXd for HER2‑expressing breast cancer with leptomeningeal or brain metastases

  This trial will try intrathecal (Ommaya) T-DXd plus systemic therapy to see if it is safe and better controls leptomeningeal and brain metastases in people with HER2‑expressing breast cancer.

  Recruiting at 2 sites Phase 1/2 Fudan University · Shanghai, Shanghai Municipality and 1 other locations · NCT07134153

• Neoadjuvant chemoradiotherapy with or without tislelizumab for ultra-low rectal cancer – RELIEVE-02

  This study tests whether adding tislelizumab to standard chemoradiotherapy and subsequent chemotherapy improves anus preservation in adults with resectable ultra-low rectal cancer.

  Recruiting Phase 3 Fudan University · Shanghai · NCT07132463

• Zhongshan Ketogenic Diet 1: ketogenic diet effects on platelets and clotting

  This test looks at whether a 7-day ketogenic diet changes how platelets work and whether aspirin can block any increase in clotting risk for eligible adults in Shanghai.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07117903

• Sunvozertinib for untreated advanced non-small cell lung cancer with uncommon EGFR mutations

  This will test whether the oral drug sunvozertinib can shrink tumors and be safe in adults with untreated advanced non‑small cell lung cancer who have uncommon EGFR mutations.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07117890

• Disitamab Vedotin plus bicalutamide for HER2/AR-positive scrotal Paget disease

  This trial will test whether combining Disitamab Vedotin and bicalutamide helps adults with advanced HER2-positive, AR-positive extramammary Paget disease of the scrotum.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07117851

• Triple-combination therapy for HR+/HER2- advanced breast cancer after progression on standard treatment

  This study will test whether adding L-ornithine L-aspartate to a CDK4/6 inhibitor plus fulvestrant helps people with HR-positive/HER2-negative advanced breast cancer who have progressed after CDK4/6 inhibitor and endocrine therapy.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07117630

• Tislelizumab plus chemotherapy before and after surgery for resectable limited-stage small cell lung cancer

  This trial will try giving the immunotherapy drug tislelizumab with platinum‑etoposide chemotherapy before and after surgery to see if it helps adults with resectable limited-stage (IIB–IIIB) small cell lung cancer live longer or lower the chance of recurrence.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07109401

• Hepatic arterial infusion chemotherapy with camrelizumab and rivoceranib for advanced mixed hepatocellular‑cholangiocarcinoma

  This will test whether adding camrelizumab and rivoceranib to hepatic arterial infusion chemotherapy helps people with advanced mixed hepatocellular‑cholangiocarcinoma.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07105748

• Nimotuzumab plus Adebrelimab with chemotherapy for cisplatin‑ineligible head and neck cancer

  This trial will try combining nimotuzumab and adebrelimab with chemotherapy to see if the regimen is safe and helps people with recurrent or metastatic head and neck squamous cell carcinoma who cannot receive high‑dose cisplatin.

  Recruiting Phase 1/2 Fudan University · Shanghai, Shanghai Municipality · NCT07105592

• TACE plus anti-PD-1 treatment for advanced liver cancer

  This study will test whether combining TACE with a PD-1 blocker helps people with advanced hepatocellular carcinoma and how the treatment changes immune cells in tumors and blood.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07100405

• TUDCA with camrelizumab and regorafenib for advanced hepatocellular carcinoma after anti‑PD‑1/PD‑L1 plus bevacizumab

  This trial tests whether adding TUDCA to camrelizumab and regorafenib helps people with advanced hepatocellular carcinoma that got worse after anti‑PD‑1/PD‑L1 plus bevacizumab.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07100392

• Cryoablation with lenvatinib and QL1706 for advanced intrahepatic cholangiocarcinoma

  We will try freezing tumors (cryoablation) together with the drugs lenvatinib and QL1706 in people whose advanced intrahepatic cholangiocarcinoma has worsened after first-line treatment.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07070700

• Predicting response to first-line DLBCL treatment using ctDNA and PET/CT

  This project will test whether combining a blood ctDNA test with PET/CT scans after two treatment cycles can predict treatment response in people newly diagnosed with DLBCL who are starting standard first-line therapy.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07070648

• Tislelizumab plus capecitabine for nasopharyngeal cancer with leftover EBV DNA after radiation

  This will test whether adding the immunotherapy tislelizumab to the oral chemotherapy capecitabine helps people with nasopharyngeal cancer who still have detectable EBV DNA after radiotherapy.

  Recruiting Phase 2 Fudan University · Shanghai, China · NCT07067268

• Lenvatinib plus tislelizumab versus lenvatinib alone for advanced hepatocellular carcinoma after prior PD‑1/PD‑L1 plus bevacizumab

  This trial will test whether adding the immunotherapy tislelizumab to lenvatinib works better than lenvatinib alone for people with advanced liver cancer who progressed after prior PD‑1/PD‑L1 plus bevacizumab treatment.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07047586

• Cisplatin plus gemcitabine for adults after PD‑1 therapy failure or with certain rare advanced tumors

  This study will test whether the chemotherapy combination cisplatin plus gemcitabine can shrink advanced solid tumors in adults whose cancer progressed after PD‑1 therapy or who have certain rare aggressive tumors.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07046650

• Adding a CDK4/6 blocker to hormone treatment after surgery for high-risk HR+/HER2+ early breast cancer

  This trial tests whether adding a CDK4/6 inhibitor to standard hormone therapy after surgery helps women aged 18–70 with high-risk HR+/HER2+ early breast cancer.

  Recruiting Phase 3 Fudan University · Shanghai · NCT07019363

• RGL-305 cell reinfusion for lymphoma patients with positive minimal residual disease after response to standard therapy.

  This trial will test whether RGL-305 cell reinfusion is safe and can reduce minimal residual disease in adults with lymphoma who achieved a complete or partial response but remain MRD-positive after standard treatment.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07006012

• Cadonilimab plus an anti-angiogenic drug for metastatic dMMR/MSI-H colorectal cancer

  We will try cadonilimab together with an anti-angiogenic drug in people with metastatic dMMR/MSI‑H colorectal cancer, including those who are new to PD‑1/PD‑L1 therapy and those who have had it before.

  Recruiting Phase 2 Fudan University · Shanghai, China · NCT07003022

• Pola‑R‑GemOx chemotherapy for relapsed/refractory DLBCL in patients who cannot have an autologous transplant

  This trial will test whether adding polatuzumab vedotin to rituximab, gemcitabine, and oxaliplatin helps people with relapsed or refractory DLBCL who are not eligible for autologous stem‑cell transplant.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07001540

• Oral capecitabine plus trastuzumab versus paclitaxel plus trastuzumab for small HER2‑positive, node‑negative breast cancers as adjuvant treatment.

  This trial tests whether giving oral capecitabine with trastuzumab instead of paclitaxel with trastuzumab can prevent recurrence in women with small (≤2 cm), HER2‑positive, node‑negative breast cancer.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT06992882

• Combining GemCis with PD-1/PD-L1 inhibitors for advanced biliary tract cancer

  This study is testing if combining a chemotherapy treatment with immune therapy can help people with advanced biliary tract cancer feel better and live longer.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT06988592

• Frontal vibration to improve sleep and memory in chronic insomnia

  This study will test whether gentle low‑intensity vibrations applied to the forehead help adults with chronic insomnia sleep better and improve memory.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT06983275

• Tunlametinib for advanced NRAS‑mutant thyroid cancer

  This trial tests whether the MEK inhibitor tunlametinib, alone or with a PD‑1 immunotherapy, can shrink or control tumors in adults with advanced NRAS‑mutant thyroid cancer that is refractory to radioactive iodine.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06970353

• Evaluating a new treatment for relapsed or refractory NK/T-cell lymphoma

  This study is testing a new combination treatment for people with relapsed or hard-to-treat NK/T-cell lymphoma to see if it can help them when other treatments haven't worked.

  Recruiting Phase 1/2 Fudan University · Shanghai, Shangai · NCT06966154

• Observing the effects of Sacituzumab Govitecan in metastatic breast cancer

  This study is testing how well Sacituzumab Govitecan works and how safe it is for people with metastatic HER-2 negative breast cancer who have already tried at least two other treatments.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT06966141

• Combining toripalimab and endostatin for treating stage II melanoma

  This study is testing if combining a new cancer drug with another treatment can help people with stage II melanoma live longer without their cancer coming back after surgery.

  Recruiting at 4 sites Phase 2 Fudan University · Shanghai, Shanghai Municipality and 3 other locations · NCT06965231

• Radiotherapy followed by immunotherapy for advanced esophageal cancer

  This study is testing if a new type of radiation therapy followed by an immune-boosting treatment can help adults with advanced esophageal cancer feel better and improve their health.

  Recruiting Phase 3 Fudan University · Shanghai · NCT06964568

• Stool-based multi-target DNA screening for stomach cancer

  This project tests whether a stool multi-target DNA test (detecting Helicobacter pylori genes and methylated DNA markers) can help find stomach cancer earlier in people aged 40 and over.

  Recruiting Fudan University · Tongling · NCT06943807

• Gastric cancer screening using stool H. pylori high-risk gene testing and a risk questionnaire

  We are testing whether a stool H. pylori genetic risk test plus a short risk questionnaire can find gastric cancer earlier in adults aged 40 and older.

  Recruiting Fudan University · Tongling · NCT06943781

• Probiotics plus intensified hyperfractionated chemoradiation with adebrelimab maintenance for limited-stage small cell lung cancer

  This trial tests whether adding probiotics and an intensified hyperfractionated radiotherapy plan to chemo, followed by adebrelimab maintenance, helps people with limited-stage small cell lung cancer.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06943235

• Impact of surgical margin width on recurrence and survival in liver cancer from colorectal metastasis

  This study is testing whether having wider surgical margins during liver surgery for colorectal cancer spread can help patients live longer and have fewer recurrences of cancer.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT06934018

• Comparing two types of radiotherapy for locally recurrent rectal cancer

  This study is testing if a new type of radiotherapy combined with immunotherapy can help people with locally recurrent rectal cancer live longer without their cancer getting worse compared to standard radiotherapy.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06928584

• Tamoxifen treatment for advanced pancreatic tumors

  This study is testing if tamoxifen can help people with advanced pancreatic tumors that can't be removed or have spread, especially for those with hormone receptor-positive tumors.

  Recruiting Phase 2 Fudan University · Shanghai · NCT06914674

• Using TQB2450 and progestin to treat early endometrial cancer while preserving fertility

  This study is testing if a new combination of an immune therapy and progesterone can effectively treat early endometrial cancer in young women who want to keep their ability to have children.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06914297

• SNF-guided neoadjuvant therapy for HR-positive/HER2-negative breast cancer

  This trial will test whether giving chemotherapy selected by SNF subtype with targeted drugs before surgery helps people with early or locally advanced HR-positive/HER2-negative breast cancer.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT06913777

• Using advanced imaging technology for early-stage breast cancer surgery

  This study is testing a new imaging tool during breast cancer surgery to see if it can help doctors find lymph nodes more accurately and improve treatment for patients.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT06911528

• Monitoring blood markers to predict colorectal cancer recurrence after surgery

  This study is testing if blood markers can help predict if colorectal cancer will come back after surgery in patients who have had their cancer completely removed.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT06903325

Showing recruiting studies first, then the newest. Describe your situation to find the ones that fit you.

Quick answers

How many clinical trials run by Fudan University are recruiting right now?

335, as of November 12, 2026. 4 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 141, Phase 3: 52, Phase 1/2: 14, Phase 4: 8. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →